Table 8 Definition criteria of type V myocardial infarction

1. In patients with normal baseline CK-MB or cTn (I or T)

The peak CK-MB measured within 48 h of the procedure rises to ≥10 × the local laboratory upper limit of normal (ULN), or to ≥5 × ULN with new pathologic Q-waves in ≥2 contiguous leads or new persistent LBBB, OR in the absence of CK-MB measurements and a normal baseline cTn, a cTn (I or T) level measured within 48 h of the procedure rises to ≥70 × the local laboratory ULN, or ≥35 × ULN with new pathologic Q-waves in ≥2 contiguous leads or new persistent LBBB.

2. In patients with elevated baseline CK-MB (or cTn) in whom the biomarker levels are stable or falling

The CK-MB (or cTn) rises by an absolute increment equal to those levels recommended above from the most recent pre-procedure level.

3. In patients with elevated CK-MB (or cTn) in whom the biomarker levels have not been shown to be stable or falling

The CK-MB (or cTn) rises by an absolute increment equal to those levels recommended above plus new ST-segment elevation or depression plus signs consistent with a clinically relevant MI, such as new onset or worsening heart failure or sustained hypotension.